Beiersdorf account plan
Global leader in skin care
At a glance
Beiersdorf is a Hamburg skin care and adhesives group (NIVEA, Eucerin, La Prairie, tesa) with €9,852 million sales in 2025 and 22,399 employees.
Beiersdorf is a Hamburg-based, DAX-listed skin care group with two independently run segments: Consumer (NIVEA, Eucerin, Aquaphor, Hansaplast, La Prairie, Chantecaille), 83.0% of 2025 Group sales, and tesa (adhesive tapes and self-adhesive solutions), 17.0%. It has over 190 affiliates and 22,399 employees (December 31, 2025); maxingvest GmbH & Co. KGaA holds a majority interest. In FY2025 Group sales were €9,852 million with 2.4% organic growth, EBIT excluding special factors €1,378 million (14.0% margin) and profit after tax €955 million. 2025 sales were 44.1% Europe, 30.5% Africa/Asia/Australia and 25.4% Americas.
Business units
NIVEA (including Labello)
€5,529 million FY2025 sales (about 56% of Group sales)The mass-market skin and personal care brand, overseen on the Executive Board by Grita Loebsack. It grew only 0.9% organically in 2025 and fell 6.8% organically in H1 2026 to €2,703 million, prompting an 18-month turnaround plan.
Derma (Eucerin, Aquaphor)
€1,492 million FY2025 sales (about 15% of Group sales)Dermo-cosmetics that grew 11.7% organically in 2025 and 7.8% in H1 2026, driven by Thiamidol, the Epicelline epigenetic serum and white-space entries such as Japan. The CEO holds Derma, with Burcu Andreae-Nehlsen on the Executive Committee.
Health Care (Hansaplast, Elastoplast, CURITAS)
€299 million FY2025 sales (about 3% of Group sales)Plasters and wound care, market leader with share gains; grew 9.3% organically in 2025 and 4.0% in H1 2026, helped by the Second Skin Protection Plaster.
Luxury (La Prairie, Chantecaille)
La Prairie €478 million FY2025 sales (about 5% of Group sales)Selective cosmetics under Oswald Barckhahn. La Prairie fell 4.5% organically in 2025 on China travel retail and fell 6.9% in H1 2026, but returned to growth in Q2; Chantecaille was a growth driver in North America.
tesa
€1,676 million FY2025 sales (17.0% of Group sales)Adhesive tapes and self-adhesive solutions for industry, craft and consumers, headquartered in Norderstedt with 5,316 employees; CFO Astrid Hermann is responsible for tesa SE. It grew 1.8% organically in 2025 on electronics and Asia, with a 16.1% EBIT margin, and fell 0.9% in H1 2026.
Strategic priorities
- NIVEA turnaround
- An 18 months turnaround plan launched in August 2026 broadens NIVEA beyond face care to deodorant and body care, keeps face care accessible, gives China, the US, India, Japan and Brazil more local flexibility, and adds €100 million of consumer-facing investment in H2 2026.
- Win with Care strategy
- The vision of being the best skin care company in the world rests on Undisputed Authority in Skin Care, Consumer-Facing Omnipresence and Performance with Purpose, supported by people and digitalisation.
- Derma and science platforms
- Thiamidol is now a EUR 500 million franchise; Epicelline epigenetics is rolling out globally, and a PROBIOM8 microbiome acne product is due under Eucerin in H2 2026.
- Less dependence on NIVEA through M&A
- Management wants acquisitions preferably in luxury and derma, including the intermediate space between La Prairie and Chantecaille.
- Mid-term return to growth
- Net sales growth returning in 2027 with a stable EBIT margin, profitable above-market growth from 2028, and free cash flow of at least 50% of EBITDA.
Latest results
In H1 2026 Group sales fell 3.5% organically and 4.5% nominally to €4,952 million, and EBIT excluding special factors fell to €768 million, a 15.5% margin (H1 2025: 16.1%). The decline came from NIVEA and Labello (-6.8% organic), hit by slower markets, European retailer conflicts, the Middle East conflict and a weak sun season, while Derma grew 7.8%. tesa fell 0.9% organically on weaker electronics. On August 3, 2026 guidance was cut: Consumer and Group organic sales are now expected to decline in the low single-digit range, with EBIT margins of at least 11.0% for Consumer and at least 11.8% for the Group. Free cash flow was €199 million and net liquidity €4,045 million.
Investments and deals
- Manufacturing and logistics capex
- Capex of €463 million in 2025, including the new Leipzig plant and logistics center and expansions in Poland and Mexico; H1 2026 capex was €180 million, including the Leipzig distribution center (€43 million) and capacity in Poland, Mexico and Brazil (€42 million).
- Hamburg innovation center
- A €139 million innovation center of about 14,000 m² on the Hamburg campus, due to open in 2028; R&D spending was €365 million in 2025.
- Share buybacks
- A €501 million buyback in 2025 and a new buyback of up to €750 million over two years, started on May 6, 2026.
- Portfolio moves
- Maestro was divested in China; S-Biomedic was acquired in full in 2022 and underpins the microbiome platform.
Challenges and risks
- NIVEA weakness
- NIVEA lost share to local, indie and Korean brands; the CEO said the overinvestment in premium face care damaged its value-for-money positioning, and the recovery is progressing slower than anticipated.
- Middle East crisis and costs
- The crisis is raising material and logistics costs and dampening consumer spending, particularly in the mass market; Consumer gross margin fell 100 basis points to 61.0% in H1 2026.
- Retail concentration and conflicts
- Retail concentration is rated a likely risk; European retailer conflicts explained 30% of the NIVEA sell-in versus sell-out gap in H1 2026.
- tesa end-market exposure
- tesa depends on smartphones and China; it faces lower electronics volumes, falling automotive production and semiconductor shortages as a risk for H2 2026.
- Luxury travel retail
- La Prairie was hit by China travel retail and a US department store crisis, with travel retail still weak in Western Europe in H1 2026.
What leadership says
“Restoring NIVEA's strength is a key priority for 2026.”
“We need to be less dependent on NIVEA.”
“We are not good enough in the rhythm”
“We have never been particularly strong in acquisitions. This is an area we are currently strengthening.”
Where a supplier can help
- Faster product development and contract manufacturing
- Tied to the NIVEA turnaround and the CEO's admission on time to market: third-party makers, formulation partners and agile packaging suppliers can shorten launch cycles.
- Digital and influencer marketing
- Tied to the €100 million extra consumer-facing investment and the Consumer-Facing Omnipresence choice: e-commerce, retail media and influencer platforms support local NIVEA franchises.
- Supply chain resilience and cost
- Tied to the Middle East cost challenge and the Leipzig and Poland capex: logistics, freight, procurement and energy-cost solutions help defend gross margin.
- Electronics and automotive adhesive applications
- Tied to tesa's end-market exposure: materials, equipment and testing partners for battery bonding, EV tapes and electronics mounting fit its innovation work.
- M&A advisory in luxury and derma
- Tied to the priority of reducing dependence on NIVEA through acquisitions in luxury and derma.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Beiersdorf?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Beiersdorf Annual Report 2025
- Beiersdorf (Hamburg, DAX, ISIN DE0005200000) is a skin care group with two independently run segments: Consumer (NIVEA, Eucerin, Aquaphor, Hansaplast, La Prairie, Chantecaille; 83.0% of 2025 Group sales) and tesa (adhesive tapes and self-adhesive solutions; 17.0%). It has over 190 affiliates and 22,399 employees (headcount, Dec. 31, 2025); maxingvest GmbH & Co. KGaA holds a majority interest.
- FY2025: Group sales €9,852 million (previous year €9,850 million), organic growth 2.4% (2024: 6.5%), with currencies taking 2.4 percentage points off nominal growth. EBIT excluding special factors €1,378 million, margin 14.0% (13.9%); profit after tax €955 million; EPS €4.25; dividend held at €1.00 per share.
- Consumer grew 2.5% organically to €8,176 million, EBIT margin (excl. special factors) 13.6%. Derma (Eucerin, Aquaphor) grew 11.7% organically to €1,492 million and Health Care 9.3% to €299 million, while NIVEA (incl. Labello) grew only 0.9% (€5,529 million) and La Prairie fell 4.5% (€478 million).
- tesa grew 1.8% organically to €1,676 million with a 16.1% EBIT margin; electronics (smartphones, tablets) and Asia (+6.6% organic) drove growth while European automotive was weak.
- Strategy "Win with Care" (vision: best skin care company in the world) rests on three choices: Undisputed Authority in Skin Care, Consumer-Facing Omnipresence, Performance with Purpose. Key science platforms: Thiamidol (hyperpigmentation), Epicelline (epigenetic anti-aging), microbiome research.
- NIVEA "rebalancing" for 2026: broaden focus beyond face care to deodorant and body care, keep face care accessible, and give key markets (China, US, India, Japan, Brazil) more local flexibility. The CEO expects meaningful improvements "later this year and in 2027".
- Investments: capex €463 million, including the Leipzig plant and logistics center and the Poland and Mexico sites; a €139 million innovation center in Hamburg opening in 2028; R&D spending €365 million and 1,849 R&D staff. E-commerce grew 20% organically.
- Capital returns: €501 million share buyback in 2025; on March 2, 2026 a new buyback of up to €750 million over two years was resolved. Net liquidity was €4,088 million and the equity ratio 68%.
- 2026 guidance (March 2026): organic sales flat to slightly growing for Consumer, tesa and the Group, with EBIT margins (excl. special factors) slightly below the 2025 level. The main risks named are geopolitical and economic instability, US tariffs, retail concentration, critical-ingredient regulation and cybersecurity.
- Beiersdorf Half-Year Report 2026
- H1 2026: Group sales €4,952 million, -3.5% organic and -4.5% nominal; EBIT excluding special factors €768 million, margin 15.5% (H1 2025: 16.1%); profit after tax €558 million; EPS €2.52.
- Consumer: -4.0% organic to €4,113 million, EBIT margin 15.4%. NIVEA and Labello fell 6.8% organically to €2,703 million, while Derma (Eucerin, Aquaphor) grew 7.8% to €837 million and Health Care 4.0% to €164 million; La Prairie fell 6.9% to €224 million but returned to growth in Q2.
- tesa: -0.9% organic to €839 million, EBIT margin 16.2%. Electronics fell against a high prior-year base and lower electronics production; Electrical Systems, Industrial Trade & Converting and Printing & Packaging Solutions grew.
- By region, Europe fell 5.3% organically; Consumer Eastern Europe fell 8.8%; the Middle East was "challenging"; Japan, India, Thailand, Brazil and China grew.
- Guidance cut (August 3, 2026): Consumer and Group organic sales now expected to decline in the low single-digit range; Consumer EBIT margin (excl. special factors) at least 11.0%, Group at least 11.8%; tesa unchanged (flat to slightly positive sales, margin slightly below the prior year).
- Risks: the Middle East crisis is raising material and logistics costs and dampening consumer spending, particularly in the mass market. Opportunities: Thiamidol in the US and China, the Derma Epigenetics rollout, and NIVEA "Rebalancing".
- Cash: free cash flow €199 million (H1 2025: -€71 million); net liquidity €4,045 million. A share buyback of up to €750 million over two years started on May 6, 2026; the dividend was €1.00 per share (€219 million).
- Headcount 22,326 (Consumer 17,026, tesa 5,300). Capex €180 million, including the Leipzig distribution center (€43 million) and capacity in Poland, Mexico and Brazil (€42 million).
- Beiersdorf H1 2026 results conference call (transcript)
- H1 2026 results call (August 5, 2026) with CEO Vincent Warnery and CFO Astrid Hermann: the full-year guidance was cut and an "18 months turnaround plan" for NIVEA was launched; profitable growth is targeted "from 2028".
- Q2: NIVEA -6.7% organic, Derma +7.4%, Health Care +6.2%, La Prairie +2.2% (after -14.9% in Q1), Consumer -3.3%, tesa +2.5%, Group -2.3%.
- Derma: Q2 growth of 71% in Brazil and 62% in China; US face care +40% organically. Aquaphor is entering body lotions and creams, which Warnery called "the largest U.S. launch to date".
- NIVEA plan: growth across the full category portfolio, more focus on accessibility and value for money (most products cost €2-10), local franchises (NIVEA Facial / Face Plus, Softgel in India), and €100 million of extra consumer-facing investment in H2 2026.
- The gap between NIVEA sell-in and sell-out is explained as 30% retailer conflicts (deals now cover 92% of the European business), 50% destocking and sun phasing, and 20% route-to-market changes such as in Malaysia and the Philippines.
- New 2026 guidance: Consumer and Group organic sales down low single digits; Consumer EBIT margin of at least 11% (2025: 13.6%), Group at least 11.8% (2025: 14%). Mid-term: sales growth returning in 2027, profitable above-market growth from 2028, and free cash flow of at least 50% of EBITDA.
- Capital allocation: M&A is to make the group less dependent on NIVEA, preferably in luxury and derma; the €750 million buyback is confirmed. Coppertone is "on the verge of being profitable"; Maestro was divested in China.
- Beiersdorf full year 2025 results conference call (transcript)
- FY2025 results call (March 3, 2026), CEO Vincent Warnery and CFO Astrid Hermann: the skin care market slowed from mid-single digits to "around 1.5% to 2%"; Beiersdorf's skin care business grew 3.7% and the group claims to be the best-performing skin care company "for the third year in a row".
- Derma reached a record EUR 1.5 billion, close to 20% of consumer sales, with double-digit growth for the fifth year. Thiamidol is now a EUR 500 million franchise. A PROBIOM8 microbiome acne product (S-Biomedic) is due under Eucerin DERMOPURE CLINICAL in H2 2026.
- NIVEA grew 0.9%, which Warnery put down to a weaker market, the China repositioning and a back-loaded innovation calendar. The rebalancing shifts spending from premium face care, the most media-intensive category, to deodorant, body care and accessible face care, with "Freedom, in a frame" for local markets.
- Five-year record: net sales up almost 30% to EUR 9.9 billion, EBIT excluding special factors up almost 40%, e-commerce 17% of 2025 sales, and the North America consumer business at EUR 1 billion.
- La Prairie fell 4.5% in 2025 (+3.8% in Q4). Q1 2026 was expected to fall by double digits because of the US department store crisis and travel retail changes in China; a new franchise priced at EUR 150-300 and a launch on Amazon US are planned.
- 2026 guidance: sales flat to slightly growing, margins slightly below 2025, Q1 negative low single digit. No mid-term margin number is quoted. M&A is a priority ("we have a portfolio which is much too small"); there is a new buyback of up to EUR 750 million and a EUR 1 dividend.
- Tariffs: about 90% of products sold in the US are made in Mexico (USMCA) or the US, so Beiersdorf will not join the tariff refund lawsuits.
- "Remaining in the Russian market was the most difficult decision I have had to make as CEO" - Vincent Warnery (ESSEC Alumni)
- Interview of CEO Vincent Warnery (ESSEC class of 1991) by ESSEC Alumni, published April 6, 2026. The text is an automatic translation from French, so quotes below are translations.
- On risk: a diversified industrial base and agile freight keep products moving. US products are made in Mexico and the US, so Beiersdorf is "not affected by European surcharges", but it is hit by the closure of the Strait of Hormuz.
- On Russia: staying was "the most difficult decision" of his tenure. Beiersdorf cut the range by two-thirds, halted advertising and withdrew La Prairie; the decision was shaped by the post-war loss and slow buy-back of NIVEA's international rights.
- On growth: Beiersdorf is "strengthening" acquisitions and wants to expand "in the intermediate space" between La Prairie (products up to €2,000) and Chantecaille (€100–150).
- Organic growth stays the main driver: Eucerin grew from €500 million to €1.5 billion in revenue in nine years, and Thiamidol (launched 2017) alone generates "several hundred million euros".
- On brands: NIVEA's blue tin carries loyalty across generations; influencers have replaced TV spots; consumers want proven, research-based efficacy, which "is very good news" for Beiersdorf.
Questions about Beiersdorf
What does Beiersdorf do?
Beiersdorf makes skin and personal care products under brands such as NIVEA, Eucerin, Aquaphor, Hansaplast, La Prairie and Chantecaille, and adhesive tapes and self-adhesive solutions through tesa.
What was Beiersdorf's revenue in 2025?
Group sales were €9,852 million in FY2025, with 2.4% organic growth and EBIT excluding special factors of €1,378 million (14.0% margin).
How many employees does Beiersdorf have?
22,399 employees at December 31, 2025, and 22,326 at the half-year 2026 (Consumer 17,026, tesa 5,300).
Who leads Beiersdorf?
Vincent Warnery is CEO and Astrid Hermann is CFO, also responsible for tesa SE. The Supervisory Board is chaired by Prof. Dr. Reinhard Pöllath.
What is Beiersdorf's strategy?
Under Win with Care it aims to be the best skin care company in the world, with a NIVEA turnaround, Derma growth through Thiamidol and Epicelline, and acquisitions in luxury and derma; it targets profitable above-market growth from 2028.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)